MAIA Biotechnology Expands THIO-101 Trial with Winship Enrollment
CHICAGO, June 18, 2026 MAIA Biotechnology, Inc. announced that Winship Cancer Institute of Emory University, Georgia’s only National Cancer...
non-small cell lung cancer
Advertisement
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Advertisements
Leads Biolabs’ Opamtistomig Shows Strong NSCLC Response Ahead of WCLC 2026
NANJING, China, May 28, 2026 Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB...
Ellipses Pharma and Kelun-Biotech Present EP0031 Data at ASCO 2026
LONDON, May 22, 2026 Ellipses Pharma and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that pivotal Phase 2 clinical trial...
Innovent’s IBI363 Shows Strong First-Line NSCLC Data
SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
A2 Bio Reports First CAR-T Complete Response in Lung Cancer
CHICAGO, Illinois, 21 May 2026 A2 Biotherapeutics, Inc. announced new safety and efficacy results from its ongoing EVEREST-2 Phase...
Advertisement
